Health-Related Quality of Life in Mild-Moderate Patchy Alopecia Areata: Results from the First Controlled Phase 2 Clinical Trial with STS01 (Dithranol/ProSilic) and Future Challenges
April 2026
in “
medRxiv
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → 
Studysummary In a phase 2 trial, researchers tested a topical formulation for alopecia areata and found significant hair regrowth with the treatment, but these improvements did not lead to substantial enhancements in health-related quality of life.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
A phase 2, randomized, double-blind, placebo-controlled trial investigated the effects of STS01, a topical formulation of dithranol, on mild to moderate patchy alopecia areata (AA). The study found significant, dose-related improvements in hair regrowth. However, these improvements did not correspond to significant enhancements in health-related quality of life (HRQoL), even for patients who experienced complete hair regrowth. The study highlighted challenges in using current HRQoL assessment methods, noting potential issues such as the lack of a true baseline, the development of coping mechanisms by patients, and delays between physical and psychological improvements. The trial was ethically approved and funded by Soterios LTD.
